Difelikefalin

Kappa opioid receptor agonism has always been an attractive analgesic idea — it relieves pain and itch without the respiratory depression or reinforcement of mu agonists — but classical kappa agonists produce dysphoria, sedation and hallucinations because they enter the CNS. Difelikefalin is deliberately engineered from D-amino acids with high hydrophilicity so that it stays peripheral, hitting kappa receptors on primary afferent nerve terminals and on immune cells including monocytes and T-cells. In chronic kidney disease-associated pruritus, the effect appears to come from both direct dampening of itch-transmitting afferents and reduced inflammatory signalling. The all-D backbone also makes it essentially protease-resistant, which is why it survives in plasma for a day rather than minutes. It is not metabolised by CYP450 and is cleared almost entirely renally, which is exactly why it accumulates in dialysis patients and can be dosed only three times a week.

Targets: Kappa opioid receptor (OPRK1) on peripheral sensory neurons, Kappa opioid receptors on monocytes and T-lymphocytes

• · The actual label dose is 0.5 mcg per kg of target dry body weight — that works out to about 25 mcg for a 50 kg patient and 60 mcg for a 120 kg patient. Supplied as 65 mcg in 1.3 mL. Doses are not given on non-dialysis days because clearance depends on the dialysis session.
• · Oral difelikefalin has been run in notalgia paresthetica and non-dialysis CKD pruritus across roughly the 0.25 mg to 2 mg per dose range. The exact regimen differs by trial and no oral form is approved — treat this range as descriptive of the trial programme, not as a protocol.

Work out your exact syringe units →

• commonDiarrhoea— The most frequently reported effect in the phase 3 programme.
• commonDizziness— Usually within a few hours of the dose.
• commonNausea and vomiting
• commonSomnolence and mental status change— More likely in the elderly and in anyone also taking sedating drugs; kappa agonism is not entirely absent from the CNS at higher exposure.
• commonHyperkalaemia and headache
• uncommonGait disturbance and falls— A real concern in frail dialysis patients.

• Concurrent sedating drugs, opioids, benzodiazepines or alcohol — the additive somnolence and dizziness is the main practical hazard.
• Driving or operating machinery until the individual response is known.
• There is no established use or dosing in people with normal kidney function outside of clinical trials; the whole approved regimen is built around dialysis clearance.

• cautionziconotide — Overlapping dizziness and cognitive effects with no complementary mechanism.
• cautionendomorphin-1-and-2 — Kappa and mu opioid agonism together is pharmacologically incoherent — kappa agonism partly antagonises mu-mediated reward and can worsen dysphoria.

• · Somnolence, dizziness and fall risk, particularly in the first weeks and in older patients.
• · Itch severity on a numerical or WI-NRS scale so the drug can be judged objectively rather than by impression.
• · Serum potassium as part of routine dialysis labs.

Approved prescription drug in the US and EU for a narrow dialysis indication. It is not scheduled as a controlled substance in the US because peripherally restricted kappa agonism carries no abuse liability.

• Fishbane et al. 2020, NEJM — KALM-1 phase 3 trial of difelikefalin in haemodialysis pruritus (trial)
• KALM-2 phase 3 trial of difelikefalin (trial)
• Korsuva (difelikefalin) FDA prescribing information (label)

The kappa opioid receptor has been an obviously good analgesic target for forty years and an obviously unusable one for just as long. Kappa agonism produces analgesia and suppresses itch with no respiratory depression and no reinforcing behaviour — it is, if anything, anti-addictive, because kappa activation opposes mu-mediated dopamine release in the nucleus accumbens. The problem is that the same mechanism in the same brain regions produces dysphoria, depersonalisation, sedation and hallucination so reliably that salvinorin A, a kappa agonist, is taken recreationally precisely for that effect. Every centrally penetrant kappa agonist ever put into humans has failed on this. Difelikefalin solves the problem by geometry rather than pharmacology: it is the same kappa agonism, chemically prevented from reaching the brain. Three amine groups and a free carboxylate give it a charge profile no passive transcellular route will accept, and there is no active uptake transporter for it. What remains accessible is everything peripheral — kappa receptors on the terminals of primary sensory afferents in skin and viscera, on dorsal root ganglion cell bodies, and on immune cells including monocytes, macrophages and T lymphocytes. In chronic kidney disease-associated pruritus both arms probably matter. Kappa activation on itch-transmitting C-fibres hyperpolarises the terminal and dampens firing, and the immune arm reduces the inflammatory signalling that sensitised those fibres in the first place. There is also a plausible rebalancing story: uraemic pruritus is associated with an imbalance between mu tone (pro-itch) and kappa tone (anti-itch) in skin and spinal cord, and difelikefalin pushes the kappa side back up. Downstream, kappa is a Gi/Go-coupled GPCR — it inhibits adenylyl cyclase, opens GIRK potassium channels and closes N-type calcium channels, which is the same terminal-silencing endpoint ziconotide reaches by blocking the channel directly. Worth noting how modest the clinical result is despite the elegance: in KALM-1 the responder rate was 51.9% versus 30.9% on placebo, meaning roughly one in five treated patients got a benefit attributable to the drug. That is a real, replicated, regulator-satisfying effect and it is a long way from abolishing the symptom.

The most common way this goes wrong is that it simply does not work for you, and roughly half of treated patients in the pivotal trials were in that group. Twelve weeks of three-times-weekly injections with no benefit is the modal outcome, which is why scoring the itch daily from before you start is not optional. The second failure is falls. Dialysis patients are frail, often orthostatic after a session, and difelikefalin is given at the end of the run — so the dizziness peaks exactly when the patient is standing up to leave. Older patients on other sedatives are the ones who end up on the floor. The third is misdiagnosis: itch in a dialysis patient is often driven by inadequate dialysis, hyperphosphataemia, severe hyperparathyroidism or simple xerosis, none of which a kappa agonist touches, and difelikefalin gets blamed for failing when it was aimed at the wrong problem. The fourth is a scale error in the grey-market context — difelikefalin is dosed at 0.5 micrograms per kilogram intravenously into the dialysis circuit, so roughly 25 to 60 micrograms total. That is a hundredth of a typical research-peptide dose. Anyone treating it like a normal subcutaneous peptide will be off by orders of magnitude. And the whole approved regimen depends on dialysis clearing 70-80% of the drug three times a week; in someone with working kidneys the half-life is around two hours instead of a day, so the schedule makes no sense at all.

• Kappa opioid receptor (OPRK1) on peripheral sensory neurons and dorsal root ganglia — Sub-nanomolar at KOR with selectivity over mu and delta reported in the thousands-fold range. The US label characterises it as a selective KOR agonist without publishing a Ki, and the specific numbers in circulation come from the developer's preclinical work, so no figure is asserted here.

  Gi/Go coupling: adenylyl cyclase inhibition, GIRK potassium channel opening and N-type calcium channel closure at the afferent terminal. Net result is a hyperpolarised, less excitable itch- and pain-transmitting fibre.

• Kappa opioid receptors on monocytes, macrophages and T lymphocytes — Same receptor; peripheral immune cells express functional KOR.

  Reduced pro-inflammatory cytokine signalling. This is the second proposed arm of the antipruritic effect and probably explains why the benefit builds over weeks rather than appearing with the first dose.

• Central kappa opioid receptors — Accessible only to the small fraction of drug that crosses — the design constraint the whole molecule is built around.

  Largely spared, which is why difelikefalin does not produce the dysphoria and hallucinations that killed every previous kappa agonist. Not zero, though: somnolence, dizziness and mental status change appear in the phase 3 data and get more likely with higher exposure, in the elderly, and alongside other sedatives.

• Mu opioid receptor (OPRM1) — Negligible.

  No mu activity means no respiratory depression, no euphoria, no opioid-type constipation and no abuse liability. Difelikefalin is not a scheduled substance in the US for exactly this reason.

• KALM-1 — phase 3 trial of difelikefalin in haemodialysis patients with moderate-to-severe pruritus Phase 3, randomised, double-blind, placebo-controlled · n=378 · 12 weeks · 2020

  Proportion achieving a 3-point or greater improvement from baseline in the weekly mean Worst Itch Numerical Rating Scale at week 12: 51.9% on difelikefalin 0.5 mcg/kg IV three times weekly versus 30.9% on placebo (p<0.001). Secondary itch-related quality-of-life and sleep measures also favoured difelikefalin.

• KALM-1 and KALM-2 pooled analysis Pooled analysis of two phase 3 randomised, double-blind, placebo-controlled trials · 12 weeks · 2022

  Pooling both pivotal trials confirmed the itch-intensity benefit and the improvement in itch-related quality of life at week 12, with a consistent effect size across the two studies. This is the source establishing that KALM-2 replicated KALM-1, rather than the drug resting on a single positive trial.

• Phase 2 trial of oral difelikefalin in notalgia paresthetica Phase 2, randomised, double-blind, placebo-controlled · 8 weeks · 2023

  Change in weekly mean WI-NRS with oral difelikefalin versus placebo in notalgia paresthetica — a localised neuropathic itch condition in people with normal kidney function. Positive, and the most interesting existing evidence that the drug does something outside dialysis. Still phase 2, and no oral formulation is approved.

Nothing useful happens on day one. The pharmacokinetics are immediate — this is an intravenous bolus — but the antipruritic effect is not, which itself argues the mechanism involves desensitising a sensitised system rather than acutely blocking a signal. Itch scores begin separating from placebo within the first one to two weeks in the phase 3 data. Most of the achievable benefit is present by week 8, and week 12 is where the trials made their responder judgement. If you are going to get somnolence or dizziness you will see it within hours of the first few doses, not later. Twelve weeks is therefore the right length for an adequate trial, and stopping at week 4 because it has not worked yet is stopping too early.

The stacking question that matters with difelikefalin is subtractive, not additive. Somnolence, dizziness and gait disturbance are its real-world limiting effects, and they are additive with everything else a dialysis patient is likely to be taking — gabapentin and pregabalin (both renally cleared and routinely overdosed in this population), sedating antihistamines given for the same itch, opioids, benzodiazepines and mirtazapine. Starting difelikefalin is a good moment to take gabapentin down or off, because gabapentinoids are frequently prescribed for uraemic pruritus, work poorly for it, and accumulate to toxic levels in dialysis patients. Running both and then blaming the falls on difelikefalin is the common mistake. Combining with a mu agonist is pharmacologically coherent for pain, since kappa and mu analgesia are additive at the spinal level, but kappa agonism opposes mu-driven reward and can leave people feeling flat, so do not expect the combination to be pleasant. Combining with another kappa agonist is pointless. There is nothing to worry about at the metabolic level — no CYP involvement means no dose adjustment for the long list of drugs a dialysis patient is already on, which is unusual and genuinely useful.

Against the alternatives for uraemic pruritus, difelikefalin is the only one with two positive phase 3 trials behind it. Gabapentin and pregabalin are widely used, poorly evidenced for this indication, and accumulate dangerously in dialysis patients. Antihistamines do essentially nothing for uraemic itch, which is not histamine-mediated, and just add sedation. Nalfurafine, a kappa agonist approved in Japan for the same indication, is the closest relative — but it is centrally penetrant, which is precisely the design decision difelikefalin reversed. UVB phototherapy helps some people and requires three visits a week to a different department. Against the rest of this class on the site, difelikefalin is proof that the peripherally-restricted-opioid idea can actually reach approval: DALDA was designed on the same principle three decades earlier and never got a human dose, while difelikefalin got a label. The gap between them is a competent development programme, not a better mechanism. The unresolved question is analgesia — CR845 was carried through a substantial pain programme in osteoarthritis and post-operative pain before the itch indication became the one that worked, and the evidence that it relieves pain in humans remains unconvincing.

Not priced here because I could not verify current figures in this session. In US practice difelikefalin is administered and billed as part of the dialysis encounter rather than dispensed to the patient, so an individual monthly out-of-pocket figure is not a meaningful number for most people on it. There is no self-administered or grey-market version — the dose is measured in tens of micrograms and delivered into a dialysis circuit.

• ?No binding affinity (Ki) at KOR and no selectivity ratio over mu and delta are asserted here, because the figures in circulation come from developer preclinical data I did not resolve in this session and the US label does not publish them.
• ?The Core record describes the C-terminal extension as a 'piperidine-acetic acid'; PubChem CID 24794466 gives it as 4-amino-4-carboxypiperidine amide-linked to D-Lys, and the formula C36H53N7O6 / 679.8 Da matches that structure. The Core description appears slightly off and is worth correcting there.
• ?Participant numbers for KALM-2 and for the pooled KALM-1 plus KALM-2 analysis are left null; I confirmed both publications exist but did not resolve exact enrolment figures.
• ?The participant count and precise duration of the notalgia paresthetica phase 2 trial are left null for the same reason.
• ?The roughly two-hour half-life in people with normal renal function comes from the Core record and secondary sources; the label section I retrieved gives the 23-31 hour figure for haemodialysis patients only.
• ?Time to steady state is given as approximately 5 days, derived from the label statement that steady state is reached after the second dose on a three-times-weekly schedule, rather than from a stated number of days.
• ?Oral difelikefalin bioavailability has never been published; the hundred-fold oral-to-intravenous dose gap is inference from trial dose ranges, not a measured figure.

• A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus Fishbane S, Jamal A, Munera C, et al., New England Journal of Medicine, 2020 · PMID 31702883

  KALM-1, the registration trial. 378 patients, 12 weeks, 51.9% versus 30.9% responder rate. Every claim about difelikefalin's efficacy traces here.

• Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies Topf J, Wooldridge T, McCafferty K, et al., Kidney Medicine, 2022 · PMID 36016762

  The pooled KALM-1 plus KALM-2 analysis. Use this rather than KALM-1 alone when you want to know whether the effect replicated. It did, at a similar magnitude.

• Phase 2 Trial of Difelikefalin in Notalgia Paresthetica Kim BS, Bissonnette R, Nograles K, et al., New England Journal of Medicine, 2023 · PMID 36780675

  Oral difelikefalin in a non-dialysis, normal-renal-function population with neuropathic itch. The evidence that the mechanism generalises beyond uraemic pruritus, and the reason the oral programme continued.

• KORSUVA (difelikefalin) injection, solution — US prescribing information Vifor (International), Inc., DailyMed, US National Library of Medicine

  Source of the pharmacokinetics quoted here: volume of distribution approximately 238 mL/kg, plasma protein binding 23-28% in dialysis patients, no CYP metabolism, excretion 11% urine / 59% faeces / 20% dialysate, half-life 23-31 hours pre-dialysis, 70-80% removal by a single dialysis session, steady state after the second dose with accumulation ratio up to 1.6, and the 0.5 mcg/kg dose.